Mills J S, Bailey B L, Johnson J D
Biochemistry. 1985 Aug 27;24(18):4897-902. doi: 10.1021/bi00339a026.
The binding of felodipine, a dihydropyridine Ca2+ antagonist, to calmodulin has been studied by equilibrium dialysis and fluorescence techniques. Analysis using the Hill equation gives a Hill coefficient of 2. A plot of bound [felodipine] vs. free [felodipine]2 gives a Bmax of 1.9 mol/mol and a K0.5 of 22 microM. Two calmodulin antagonists, prenylamine and R24571, which have previously been shown to potentiate the fluorescent enhancement observed when felodipine binds to calmodulin [Johnson, J. D. (1983) Biochem. Biophys. Res. Commun. 112, 787], produce a reduction in Hill coefficient to 0.7 and 1.0, respectively, and account for the observed potentiation of felodipine binding. Titrations of felodipine with calmodulin in the absence and presence of prenylamine and R24571 suggest that these drugs decrease the K0.5 of calmodulin for felodipine by 25-fold. Thus, potentiating drugs (prenylamine and R24571) bind to either of the two felodipine binding sites and, through an allosteric mechanism, result in felodipine binding to the remaining site with greatly enhanced affinity. Two types of potentiating drugs are observed. Prenylamine exhibits a Hill coefficient of 0.8 whereas felodipine, R24571, and diltiazem exhibit Hill coefficients of 2 in their potentiation of felodipine binding. Titrations of felodipine and calmodulin with Ca2+ exhibit cooperativity with a Hill coefficient of 4. Half-maximal binding occurs near pCa 6.0. In the presence of R24571, the calcium dependence of felodipine binding is biphasic, now exhibiting a much higher affinity (pCa 7.6) component. A model is presented to explain the relationship of these various allosterically regulated conformers of calmodulin and their interactions and activation with its target proteins.
采用平衡透析和荧光技术研究了二氢吡啶类钙拮抗剂非洛地平与钙调蛋白的结合情况。用希尔方程分析得出希尔系数为2。结合的[非洛地平]与游离的[非洛地平]²作图,得出最大结合量(Bmax)为1.9 mol/mol,半最大结合浓度(K0.5)为22 μM。两种钙调蛋白拮抗剂,即普尼拉明和R24571,此前已被证明可增强非洛地平与钙调蛋白结合时观察到的荧光增强[约翰逊,J. D.(1983年)《生物化学与生物物理学研究通讯》112, 787],它们分别使希尔系数降至0.7和1.0,并解释了观察到的非洛地平结合增强现象。在不存在和存在普尼拉明及R24571的情况下,用钙调蛋白对非洛地平进行滴定表明,这些药物使钙调蛋白对非洛地平的K0.5降低了25倍。因此,增强药物(普尼拉明和R24571)与两个非洛地平结合位点中的任何一个结合,并通过变构机制导致非洛地平以大大增强的亲和力与剩余位点结合。观察到两种类型的增强药物。普尼拉明的希尔系数为0.8,而非洛地平、R24571和地尔硫䓬在增强非洛地平结合时的希尔系数为2。用Ca²⁺对非洛地平和钙调蛋白进行滴定显示出协同性,希尔系数为4。半最大结合出现在pCa 6.0附近。在存在R24571的情况下,非洛地平结合的钙依赖性呈双相性,现在表现出一个亲和力高得多(pCa 7.6)的组分。提出了一个模型来解释钙调蛋白的这些各种变构调节构象之间的关系及其与靶蛋白的相互作用和激活。